Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan 29;20(1):42.
doi: 10.1186/s13023-024-03518-x.

Identification of strengths and weaknesses of the healthcare system for persons living with rare diseases in Catalonia (Spain), and recommendations to improve its comprehensive attention: the "acERca las enfermedades raras" project

Affiliations

Identification of strengths and weaknesses of the healthcare system for persons living with rare diseases in Catalonia (Spain), and recommendations to improve its comprehensive attention: the "acERca las enfermedades raras" project

José Hernández-Rodríguez et al. Orphanet J Rare Dis. .

Abstract

Background: Rare diseases (RDs) are a heterogeneous group of complex and low-prevalence conditions in which the time to establish a definitive diagnosis is often too long. In addition, for most RDs, few to no treatments are available and it is often difficult to find a specialized care team.

Objectives: The project "acERca las enfermedades raras" (in English: "bringing RDs closer") is an initiative primary designed to generate a consensus by a multidisciplinary group of experts to detect the strengths and weaknesses in the public healthcare system concerning the comprehensive care of persons living with a RD (PLWRD) in the region of Catalonia, Spain, where a Network of Clinical Expert Units (Xarxa d'Unitats de Expertesa Clínica or XUEC) was created and is being implemented since 2015. The additional primary aim was to propose recommendations to solve or improve the limitations found.

Methods: A task force of 13 participants with multidisciplinary expertise on RDs completed a questionnaire and participated in two focus groups. A document was drafted with an item series of strengths and weaknesses of the healthcare system regarding the care of PLWRD, and a set of proposals or recommendations to overcome the problems identified.

Results: The Catalan Government healthcare model of XUECs for the comprehensive care for RDs is currently valid and adapted to the needs of PLWRD and their families since its strategic optimal and operational framework, and it is aligned with the European Reference Networks (ERNs) thematic areas. The problems found in the current healthcare model were grouped into ten main areas: (1) the healthcare model for RDs; (2) coordination with primary healthcare providers and other tertiary and secondary hospitals; (3) access to and coordination with non-medical services; (4) the role of case manager in the XUEC; (5) genetic diagnosis; (6) undiagnosed patients; (7) treatments; (8) referring process, continuous follow-up, and transition from pediatric to adult centers; (9) research and education for professionals; and (10) associations of PLWRD and their families (patients' advocacy). The need for more resources was currently detected as the common factor for most of them. Ten key recommendations to improve the healthcare system regarding RDs were postulated.

Conclusions: Catalonia has established a unique healthcare model for RDs in Spain, with clear strengths and advantages. However, after analyzing them, the experts suggested that new governmental political and administrative decisions are needed to ensure the efficient implementation of a healthcare plan for PLWRD in Catalonia, which could be applied to other regions and nations worldwide.

Keywords: Comprehensive care; Focus group; Healthcare system; Patient journey; Person living with a rare disease; Rare diseases.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: As this study was classified as a consensus development technique and did not involve research on patients, obtaining approval from an ethics committee or internal review board was not necessary. All the clinicians who participated in this study willingly served as panelists, agreed with the objectives of the modified Delphi panel study. Consent for publication: All the participants in this study signed an inform consent allowing the publication of the resulting manuscript. Competing interests: All the authors received consulting fees for this study from Sobi. The funder had no role in the design and conduct of the study, or collection, management, analysis, and interpretation of the data.

Similar articles

References

    1. Wallis C. Adopting orphan drugs: congress tries to encourage new remedies for rare diseases. Time. 1982;120(15):76–9. - PubMed
    1. Posada M, Martin-Arribas C, Ramirez A, Villaverde A, Abitua I. Rare diseases. Concept, epidemiology and state of the question in Spain [Enfermedades raras. Concepto, epidemiología y situación actual en España]. An Sist Sanit Navar. 2008;31(Suppl 2):9–20. - PubMed
    1. Asociación Española de Laboratorios de Medicamentos Huérfanos y Ultrahuérfanos. Access report: orphan drugs in Spain in 2023 [Informe de acceso: Los medicamentos huérfanos en España en 2023]. https://aelmhu.es/informes-de-acceso/ (2024). Accessed 8 Mar 2024.
    1. FEDER. Learn more about rare diseases: frequently asked questions [Conoce más sobre las Enfermedades Raras: Preguntas Frecuentes]. https://www.enfermedades-raras.org/enfermedades-raras/conoce-mas-sobre-e... (2020). Accessed 8 Mar 2024
    1. European Commission. Rare diseases. https://research-and-innovation.ec.europa.eu/research-area/health/rare-d... (2023). Accessed 8 Mar 2024.

LinkOut - more resources